Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Joint Replacement Patients With Diabetes Greatly Benefit From Controlled Glucose
Diabetics undergoing total joint replacement often are at a higher risk of experiencing complications after surgery due to various pre-existing health conditions. According to a new study published in the July 2009 issue of The Journal of Bone and Joint Surgery (JBJS), those complications are less likely to occur when a diabetic patient has glucose levels under control.
generic viagra online
"Artificial Golgi" May Provide New Insight Into Key Cell Structure
Scientists in New York and North Carolina are reporting assembly of the first functioning prototype of an artificial Golgi organelle. That key structure inside cells helps process and package hormones, enzymes, and other substances that allow the body to function normally. The lab-on-a-chip device could lead to a faster and safer method for producing heparin, the widely used anticoagulant or blood thinner, the researchers note. Their study is scheduled for the Aug. 12 issue of the Journal of the American Chemical Society, a weekly publication.
News of the day
Abbott's TRILIPIX® (fenofibric Acid) In Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia And Type 2 Diabetes Meet Amer
Abbott"s (NYSE: ABT) TRILIPIX® (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium achieved individual and combined lipid targets in patients with mixed dyslipidemia and type 2 diabetes. In these patients, the combination of TRILIPIX and rosuvastatin helped up to three times more patients simultaneously reach all three key lipid targets HDL, triglycerides and LDL than the pre-determined monotherapy. Results from this post-hoc analysis were presented at the American Diabetes Association"s 2009 Scientific Sessions.
Cardiovascular

Combination Clomiphene Citrate And Antioxidant Therapy For Idiopathic Male Infertility: A Randomized Controlled Trial

UroToday.com - Empirical medical treatment for idiopathic male factor infertility is a controversial issue. Several medications are used empirically for the treatment of idiopathic male factor infertility, including follicle stimulating hormone (FSH), antiestrogen, L-carnitine, and antioxidants. In this study, we attempted to evaluate the effectiveness of the combination of clomiphene citrate and vitamin E in the management of men with idiopathic infertility. The study was designed as a prospective, randomized, placebo-controlled trial. The setting was the outpatient Andrology clinic, in Cairo University Hospitals. The study included sixty infertile men with idiopathic oligoasthenozoospermia. Patients were randomly assigned to two treatment groups: a group receiving the combination of clomiphene citrate (25 mg/day) and vitamin E (400 mg/day; n = 30) against a placebo group (n = 30). Treatment was continued for 6 months. The main outcome measures were the pregnancy rate and variations in semen parameters. The study followed an intention-to-treat analysis. A significantly higher pregnancy rate was found among the combination treatment group in comparison to the control group. The odds ratio was 3.76 and the 95% confidence interval was 1.03-13.64, with a 36.7% pregnancy rate (11/30) in the combination treatment group compared with 13.3% pregnancy rate (4/30) in the control group. The trial showed a significantly higher increase in sperm count and progressive sperm motility with insignificant changes in total sperm motility, percentage of abnormal forms and semen volume in the combination treatment group as compared to the control group. We conclude that the combination of clomiphene citrate as an antiestrogen and vitamin E as an antioxidant can significantly increase the pregnancy rate and improve sperm count and progressive sperm motility in cases of idiopathic oligoasthenozoospermia, with normal testicular size, normal or low normal FSH, and no known male or female factors. The treatment protocol is inexpensive, safe and easy to administer. Written by Hussein Ghanem, MD, Osama Shaeer, MD, and Amgad El-Segini, MD as part of Beyond the Abstract on UroToday.com. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009